C
Cindy Casaceli
Researcher at University of Rochester
Publications - 19
Citations - 2794
Cindy Casaceli is an academic researcher from University of Rochester. The author has contributed to research in topics: Internal medicine & Randomized controlled trial. The author has an hindex of 10, co-authored 16 publications receiving 2203 citations. Previous affiliations of Cindy Casaceli include Strong Memorial Hospital.
Papers
More filters
Journal ArticleDOI
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek,Danna Jennings,Shirley Lasch,Andrew Siderowf,Caroline M. Tanner,Tanya Simuni,Christopher S. Coffey,Karl Kieburtz,Emily Flagg,Sohini Chowdhury,Werner Poewe,Brit Mollenhauer,Todd Sherer,Mark Frasier,Claire Meunier,Alice Rudolph,Cindy Casaceli,John Seibyl,Susan Mendick,Norbert Schuff,Ying Zhang,Arthur W. Toga,Karen Crawford,Alison Ansbach,Pasquale De Blasio,Michele Piovella,John Q. Trojanowski,Les Shaw,Andrew B. Singleton,Keith A. Hawkins,Jamie L. Eberling,David W. Russell,Laura Leary,Stewart A. Factor,Barbara Sommerfeld,Penelope Hogarth,Emily Pighetti,Karen Williams,David G. Standaert,Stephanie Guthrie,Robert A. Hauser,Holly Delgado,Joseph Jankovic,Christine Hunter,Matthew B. Stern,Baochan Tran,James B. Leverenz,Marne Baca,Sam Frank,Cathi A. Thomas,Irene H. Richard,Cheryl Deeley,Linda Rees,Fabienne Sprenger,Elisabeth Lang,Holly A. Shill,Sanja Obradov,Hubert H. Fernandez,Adrienna Winters,Daniela Berg,Katharina Gauss,Douglas Galasko,Deborah Fontaine,Zoltan Mari,Melissa Gerstenhaber,David J. Brooks,Sophie Malloy,Paolo Barone,Katia Longo,Tom Comery,Bernard Ravina,Igor D. Grachev,Kim Gallagher,Michelle Collins,Katherine Widnell,Suzanne Ostrowizki,Paulo Fontoura,F. Hoffmann La-Roche,Tony W. Ho,Johan Luthman,Marcel P. van der Brug,Alastair D. Reith,Peggy Taylor +82 more
TL;DR: The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials.
Journal Article
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Robert G. Holloway,Ira Shoulson,K. Kieburtz,Michael P. McDermott,Pierre N. Tariot,Cornelia Kamp,Denni Day,Aileen Shinaman,S. Fahn,Anthony E. Lang,Kenneth Marek,John Seibyl,W. Weiner,M. Welsh,R. Pahwa,S. Coe,L. Barclay,L. Sutherland,K. Hildebrand,J. Hubble,C. Weeks,P. LeWitt,J. Miyasaki,J. Duff,E. Sime,O. Suchowersky,Mark Stacy,M. Kurth,M. Brewer,M. Harrigan,D. S. Russell,B. Fussell,B. Ford,S. Dillon,J. Hammerstad,C. Stone,D. Riley,P. Rainey,David G. Standaert,M. Tennis,F. Wooten,E. Rost-ruffner,S. Factor,D. Brown,Joseph Jankovic,F. Atassi,Roger Kurlan,Irenita Gardiner,M. Panisset,D. Amyot,J. Hall,A. Rajput,Theresa Shirley,Robert L. Rodnitzky,J. Dobson,C. Shults,D. Fontaine,C. Waters,S. Schuman,R. Pfeiffer,Shirley A. Rast,B. Pfeiffer,Alicia Brocht,Cindy Casaceli,Susan Daigneault,Karen Hodgeman,K. Honsinger,C. O'Connell,Arthur Watts +68 more
TL;DR: Initial pramipexole treatment resulted in significantly less development of wearing off, dyskinesias, or on-off motor fluctuations compared with levodopa (51%) (hazard ratio, 0.45; 95% confidence interval [CI], 0.66), and the mean improvement in total UPDRS score from baseline to 23.5 months was greater in thelevodopa group than in the pramipingxole group (9.5 points; P<.001).
Journal ArticleDOI
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial
D. Angus,C. Herd,Cameron Stone,Julie C. Stout,Marguerite Wieler,Ralf Reilmann,Craig W. Ritchie,Earl Ray Dorsey,K. Helles,Elise Kayson,David Oakes,H. D. Rosas,Carr J. Vaughan,Peter K. Panegyres,David Ames,Anita M.Y. Goh,Pinky Agarwal,Andrew Churchyard,M. Murathodizic,Phyllis Chua,D. Germaine,D. L. Lim,H. Mack,Clement T. Loy,Jane Griffith,Patrick Mitchell,Jody Corey-Bloom,Shea Gluhm,Jody Goldstein,Leah Levi,Russell L. Margolis,Nadine Yoritomo,Sarah Janicki,Karen Marder,Ronda Clouse,Carlos Singer,Henry Moore,N. Padron,Sandra K. Kostyk,A. Daley,Vicki Sergo,Rajeev Ananda Kumar,Karen Anderson,Carolyn M. Drazinic,B. Hennig,Martha Nance,Eric Molho,Susan R. Criswell,Mark S. LeDoux,Shannon Guyot,Alessandro Iannaccone,Barbara J. Jennings,Blair R. Leavitt,Andrew Feigin,Scott R. Evans,S. Wray,Cindy Casaceli,Constance Orme,S. Gao,Arthur Watts,K. Baker,Izelle Labuschagne,Mays A. El-Dairi,Sharon Fekrat,Steven M. Hersch,M. Moscovitch-Lopatin,R. Ranzi,S. Targum +67 more
TL;DR: PBT2 was generally safe and well tolerated in patients with Huntington's disease and the potential benefit on executive function will need to be confirmed in a larger study.
Journal ArticleDOI
Dysregulation of Gene Expression in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Mouse Substantia Nigra
Renee M. Miller,Linda M. Callahan,Cindy Casaceli,Linlin Chen,Gretchen L. Kiser,Buena Chui,Tamma Kaysser-Kranich,Timothy J Sendera,Chockalingam Palaniappan,Howard J. Federoff +9 more
TL;DR: Microarray analysis and integrative data mining were used to uncover pathways implicated in the progression of changes in dopaminergic neurons after MPTP administration and disclosed dysregulation of genes in three main areas related to neuronal function.
Journal ArticleDOI
Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study
Tanya Simuni,Liz Uribe,Hyunkeun Ryan Cho,Chelsea Caspell-Garcia,Christopher S. Coffey,Andrew Siderowf,John Q. Trojanowski,Leslie M. Shaw,John Seibyl,Andrew B. Singleton,Arthur W. Toga,Doug R. Galasko,Tatiana Foroud,Duygu Tosun,Kathleen L. Poston,Daniel Weintraub,Brit Mollenhauer,Caroline M. Tanner,Karl Kieburtz,Lana M. Chahine,Alyssa Reimer,Samantha J. Hutten,Susan Bressman,Kenneth Marek,Vanessa Arnedo,Adrienne Clark,Mark Fraiser,Catherine Kopil,Sohini Chowdhury,Todd Sherer,Nichole Daegele,Cindy Casaceli,Ray Dorsey,Renee Wilson,Sugi Mahes,Christina Salerno,Karen Crawford,Paola Casalin,Giulia Malferrari,Mali Gani Weisz,Avi Orr-Urtreger,Thomas J. Montine,Chris Baglieri,Amanda Christini,David W. Russell,Nabila Dahodwala,Nir Giladi,Stewart A. Factor,Penelope Hogarth,David G. Standaert,Robert A. Hauser,Joseph Jankovic,Marie Saint-Hilaire,Irene H. Richard,David Shprecher,Hubert H. Fernandez,Katrina Brockmann,Liana S. Rosenthal,Paolo Barone,Alberto J. Espay,Dominic B. Rowe,Karen Marder,Anthony Santiago,Shu-Ching Hu,Stuart Isaacson,Jean-Christophe Corvol,Javiar Ruiz Martinez,Eduardo Tolosa,Yen F. Tai,Marios Politis,Debra Smejdir,Linda Rees,Karen Williams,Farah Kausar,Whitney Richardson,Diana Willeke,Shawnees Peacock,Barbara Sommerfeld,Alison Freed,Katrina Wakeman,Courtney Blair,Stephanie Guthrie,Leigh Harrell,Christine Hunter,Cathi-Ann Thomas,Raymond C. James,Grace Zimmerman,Victoria Brown,Jennifer Mule,Ella Hilt,Kori Ribb,Susan Ainscough,Misty Wethington,Madelaine Ranola,Helen Mejia Santana,Juliana Moreno,Deborah Raymond,Krista Speketer,Lisbeth Carvajal,Stephanie Carvalo,Ioana Croitoru,Alicia Garrido,Laura Marie Payne,Veena Viswanth,Lawrence Severt,Maurizio Facheris,Holly Soares,Mark A. Mintun,Jesse M. Cedarbaum,Peggy Taylor,Kevin M. Biglan,Emily Vandenbroucke,Zulfiqar Haider Sheikh,Baris Bingol,Tanya Fischer,S. Pablo Sardi,Remi Forrat,Alastair D. Reith,Jan Egebjerg,Gabrielle Ahlberg Hillert,Barbara Saba,Chris Min,Robert Umek,Joe Mather,Susan De Santi,Anke Post,Frank Boess,Kirsten I. Taylor,Igor D. Grachev,Andreja Avbersek,Pierandrea Muglia,Kaplana Merchant,Johannes Tauscher +132 more
TL;DR: The authors' data show evidence of subtle motor and non-motor signs of Parkinson's disease in non-manifesting carriers compared with healthy controls that can precede DAT deficit.